• Explore /
  • Poster
  • / A multi-center, prospective, observational study of patients with prostate cancer being treated with relugolix: OPTYX.

A multi-center, prospective, observational study of patients with prostate cancer being treated with relugolix: OPTYX.

Abstract Video & Slides Poster

Authors

Daniel Spratt

Daniel Eidelberg Spratt

University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH

Daniel Eidelberg Spratt , Rana R. McKay , Tanya B. Dorff , Benjamin H Lowentritt , Mark Fallick , Sarah Hanson , Ashley Ross

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Clinical Trial Registration Number

NCT05467176

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr TPS398)

DOI

10.1200/JCO.2023.41.6_suppl.TPS398

Abstract #

TPS398

Poster Bd #

R2

Abstract Disclosures

Similar Posters

First Author: Rana R. McKay

First Author: Jian Guan

First Author: Fred Saad

First Author: Neal D. Shore